Curis Lifesciences (NSE:CURIS) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


NSE:CURIS Curis Lifesciences Ltd NSE:CURIS
19 GF Score
Price ₹99.40
! 2 Warning Signs
View Full Analysis

What is Curis Lifesciences Research & Development?

Curis Lifesciences NSE:CURIS 19 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Curis Lifesciences's Research & Development for the six months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Curis Lifesciences  (NSE:CURIS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Curis Lifesciences Research & Development Related Terms

Curis Lifesciences Research & Development Historical Data

* Premium members only.

The historical data trend for Curis Lifesciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences Research & Development Chart

Curis Lifesciences Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00

Curis Lifesciences Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
Research & Development 0.00 0.00 0.00 0.00
NSE:CURIS
19GF Score
Curis Lifesciences Ltd NSE:CURIS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Lifesciences Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Curis Lifesciences (NSE:CURIS) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Curis Lifesciences and its competitors.
Is Curis Lifesciences' Research & Development too high?
Curis Lifesciences' current Research & Development is ₹0.0 Mil. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Research & Development compare to ZTS and UTHR?
Curis Lifesciences' Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Curis Lifesciences and its competitors. Curis Lifesciences's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curis Lifesciences Business Description

Address PF-23, GIDC Sanand - II, Industrial Acme Pharma, Opposite Teva Pharma, Sanand, Ahmedabad, GJ, IND, 382110
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score

Get the complete analysis for NSE:CURIS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹99.40
Price